Bovine Beta-Casein Peptide Inducing Mucin Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current knowledge on the regulation of gastrointestinal mucins and molecules produced by Paneth cells by nutritional factors is limited, particularly regarding the induction of mucin expression and secretion, and the stimulation of intestinal defense molecules.
Innovation Solution
A new peptide derived from bovine β-casein, corresponding to residues 94-123, is identified to induce the expression and secretion of gastrointestinal mucins, stimulate lysozyme production by Paneth cells, and increase the population of mucus and Paneth cells, offering a potential therapeutic agent for mucosal barrier enhancement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional nutritional factors are used to regulate gastrointestinal mucins, then some mucin expression is maintained, but the induction of mucin expression and secretion is limited
Solution Approach 1:
The patent identifies a specific peptide sequence (residues 94-123 of bovine beta-casein) with optimized amino acid composition and molecular weight parameters that specifically targets and induces mucin gene expression. This parameter optimization allows the peptide to effectively bind to cellular receptors and trigger mucin production pathways, achieving superior induction compared to conventional nutritional factors.
Solution Approach 2:
The invention applies the principle of local quality by designing a peptide with specific local amino acid properties - including hydrophobic regions for membrane interaction, charged residues for receptor binding, and specific motifs for nuclear translocation. These localized functional domains within the peptide enable it to perform multiple actions: crossing cell membranes, binding to transcription factors, and specifically inducing mucin gene expression in intestinal epithelial cells.
2Reliability
If Paneth cell function is enhanced to increase intestinal defense molecules, then intestinal defense is improved, but the population and activity of these cells remain limited under conventional conditions
Solution Approach 1:
The peptide modifies key parameters of Paneth cell function by inducing changes in gene expression patterns. It specifically upregulates the transcription of lysozyme and alpha-defensin genes, increases the density of Paneth cells in the intestinal crypts, and enhances the secretory activity of these cells. This parameter transformation converts conventional Paneth cell function into an enhanced defense state.
Solution Approach 2:
The peptide performs preliminary action by pre-conditioning the intestinal epithelium before pathogen challenge. It proactively increases Paneth cell population and activates defense molecule production in advance, creating a prepared state that responds more effectively to subsequent bacterial or viral infections. This preventive activation ensures rapid defense response when needed.
3Object-affected harmful factors
If the mucosal barrier is strengthened through increased mucin production, then protection against pathogens is improved, but the complexity of achieving this effect increases
Solution Approach 1:
The invention extracts the essential protective function from complex regulatory systems by identifying and isolating a single active peptide sequence (residues 94-123 of beta-casein) that can independently induce mucin production. This extracted peptide bypasses the need for complex hormonal cascades or multiple factor interactions, providing a simplified yet effective means to strengthen the mucosal barrier against acid, digestive enzymes, toxins, and pathogens.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The invention relates to a polypeptide including or consisting of SEQ ID NO: 1, or a sequence at least 80% identical to SEQ ID NO: 1, or a sequence of at least 4 consecutive amino acids included in SEQ ID NO: 1, wherein said polypeptide has at least one effect selected from: inducing the expression and/or the secretion of at least one gastrointestinal mucin; and inducing the expression and/or the secretion of at least one intestinal defense molecule expressed by Paneth cells; and inducing an increase in the population of mucus cells and/or in the population of Paneth cells, with the proviso that the polypeptide does not include the SEQ ID NO: 2 sequence.